Novartis May Sell Dermatology Generics Arm

00:43 EST 13 Nov 2017 | CHEManager

Amid estimates that the business could be worth as much as $1.5 billion, speculation is mounting that Swiss drugmaker Novartis may be planning to sell its dermatology generics arm, based mainly in the US, to concentrate on its cancer portfolio and other growth areas.

Original Article: Novartis May Sell Dermatology Generics Arm


More From BioPortfolio on "Novartis May Sell Dermatology Generics Arm"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...